Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|View printer-friendly version|
Rocket intends to use the net proceeds from this offering to fund the continued development of its pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing, and general corporate purposes.
BofA Merrill Lynch, Cowen and Evercore ISI acted as joint book-running
managers for the offering.
In addition to the shares sold in the public offering, Rocket today
announced the closing of its previously announced concurrent sale of
967,742 shares of common stock at a price of
The public offering was made by Rocket pursuant to an effective shelf
registration statement on Form S-3 that was previously filed with the
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation, the
anticipated use of the net proceeds of the offerings, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995
and other federal securities laws and are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offerings will not be
consummated, and the impact of general economic, industrial or political